Paul Hastings, Covington Guide Kyverna's Upsized $319M IPO

By Tom Zanki · February 8, 2024, 2:11 PM EST

Cell therapy firm Kyverna Therapeutics Inc. soared 36% in debut trading Thursday after completing an upsized $319 million initial public offering above its price range, guided by Paul Hastings LLP and...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login